Patient Power’s Unraveling Cancer

Is Fixed Duration Therapy the New Standard?

Patient advocate, Michele Nadeem Baker, hosts Boyu Hu, MD, Director of Lymphoma and Chronic Lymphocytic Leukemia at the Huntsman Cancer Institute at the University of Utah for a discussion on fixed duration treatment.

From Diagnosis to Treatment End: Navigating Fixed-Duration Therapy for CLL

Physician assistant Jill Miller shares what CLL patients really need to know about fixed-duration treatment. Learn how to manage side effects, what to expect month by month, when treatment ends, and how to navigate the emotional transition from active therapy to surveillance.